 Steven Bair
Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 8 | 2023 | 119 | 3.040 |
Why?
| | Immunotherapy, Adoptive | 4 | 2023 | 191 | 1.510 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 156 | 1.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 540 | 1.020 |
Why?
| | Immunoconjugates | 3 | 2021 | 89 | 0.890 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 59 | 0.650 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2019 | 131 | 0.650 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 133 | 0.640 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 194 | 0.630 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 298 | 0.610 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 197 | 0.590 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 245 | 0.550 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1974 | 0.520 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 900 | 0.460 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 94 | 0.390 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 219 | 0.390 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 287 | 0.390 |
Why?
| | Survival Rate | 3 | 2020 | 1720 | 0.270 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 15 | 0.240 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2023 | 122 | 0.220 |
Why?
| | Retrospective Studies | 8 | 2023 | 12978 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1798 | 0.190 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2020 | 72 | 0.180 |
Why?
| | Standard of Care | 1 | 2020 | 63 | 0.170 |
Why?
| | Disease-Free Survival | 2 | 2020 | 649 | 0.170 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 191 | 0.170 |
Why?
| | Humans | 17 | 2024 | 118974 | 0.170 |
Why?
| | Transplantation Conditioning | 1 | 2020 | 156 | 0.170 |
Why?
| | Remission Induction | 1 | 2019 | 247 | 0.160 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 415 | 0.160 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 8 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2021 | 9342 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1390 | 0.150 |
Why?
| | Autografts | 1 | 2017 | 49 | 0.150 |
Why?
| | Immune Tolerance | 1 | 2019 | 334 | 0.150 |
Why?
| | Precision Medicine | 1 | 2020 | 363 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 493 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 521 | 0.130 |
Why?
| | Prognosis | 2 | 2023 | 3443 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 454 | 0.130 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2014 | 26 | 0.130 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 82 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 975 | 0.120 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 26 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 671 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 969 | 0.110 |
Why?
| | Gene Dosage | 1 | 2013 | 136 | 0.110 |
Why?
| | Cardiotoxins | 1 | 2013 | 5 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2013 | 72 | 0.100 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 174 | 0.100 |
Why?
| | Aged | 3 | 2020 | 19657 | 0.100 |
Why?
| | Adolescent | 3 | 2020 | 18480 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2020 | 6561 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2014 | 345 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 394 | 0.100 |
Why?
| | Adult | 4 | 2023 | 31512 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2014 | 597 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 527 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4596 | 0.090 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 334 | 0.090 |
Why?
| | Middle Aged | 3 | 2020 | 27617 | 0.090 |
Why?
| | Patient Care Team | 1 | 2013 | 521 | 0.080 |
Why?
| | Transcription Factors | 1 | 2014 | 1570 | 0.070 |
Why?
| | Male | 3 | 2020 | 57801 | 0.060 |
Why?
| | Inflammation | 1 | 2014 | 2566 | 0.060 |
Why?
| | Female | 3 | 2020 | 61565 | 0.060 |
Why?
| | Young Adult | 1 | 2018 | 10793 | 0.060 |
Why?
| | Signal Transduction | 2 | 2014 | 4709 | 0.060 |
Why?
| | Bleomycin | 1 | 2023 | 228 | 0.050 |
Why?
| | Ki-1 Antigen | 1 | 2021 | 4 | 0.050 |
Why?
| | Vincristine | 1 | 2021 | 99 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2021 | 222 | 0.050 |
Why?
| | Rituximab | 1 | 2021 | 155 | 0.050 |
Why?
| | Prednisone | 1 | 2021 | 235 | 0.050 |
Why?
| | Doxorubicin | 1 | 2021 | 302 | 0.040 |
Why?
| | Allografts | 1 | 2020 | 135 | 0.040 |
Why?
| | Canada | 1 | 2020 | 340 | 0.040 |
Why?
| | Comorbidity | 1 | 2023 | 1527 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 2424 | 0.040 |
Why?
| | SOXF Transcription Factors | 1 | 2014 | 18 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 42 | 0.030 |
Why?
| | Transcription Initiation, Genetic | 1 | 2014 | 12 | 0.030 |
Why?
| | E-Selectin | 1 | 2014 | 52 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2014 | 80 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 74 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2013 | 18 | 0.030 |
Why?
| | Acetylation | 1 | 2014 | 217 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2014 | 152 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 134 | 0.030 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 83 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2014 | 443 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2014 | 282 | 0.030 |
Why?
| | Chromatin | 1 | 2014 | 441 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 896 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5116 | 0.020 |
Why?
| | Base Sequence | 1 | 2013 | 2159 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2366 | 0.020 |
Why?
| | Histones | 1 | 2014 | 552 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1171 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2014 | 732 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 1975 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 6471 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2871 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1323 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2680 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 907 | 0.020 |
Why?
| | Mice | 2 | 2014 | 15520 | 0.020 |
Why?
| | Macrophages | 1 | 2014 | 1324 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2851 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4077 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4908 | 0.020 |
Why?
| | Animals | 2 | 2014 | 33381 | 0.010 |
Why?
|
|
Bair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|